These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 21365461

  • 1. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
    Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.
    Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
    [Abstract] [Full Text] [Related]

  • 2. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A.
    Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
    [Abstract] [Full Text] [Related]

  • 3. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
    Kanis JA, Barton IP, Johnell O.
    Osteoporos Int; 2005 May; 16(5):475-82. PubMed ID: 15875093
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P.
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [Abstract] [Full Text] [Related]

  • 8. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
    Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL.
    Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
    [Abstract] [Full Text] [Related]

  • 9. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
    Kendler DL, Marin F, Geusens P, López-Romero P, Lespessailles E, Body JJ, Minisola S.
    Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
    [Abstract] [Full Text] [Related]

  • 10. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G.
    Cochrane Database Syst Rev; 2003 Jan; (4):CD004523. PubMed ID: 14584020
    [Abstract] [Full Text] [Related]

  • 11. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
    Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY.
    Osteoporos Int; 1997 Jan; 7(5):488-95. PubMed ID: 9425508
    [Abstract] [Full Text] [Related]

  • 12. Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
    Siris ES, Simon JA, Barton IP, McClung MR, Grauer A.
    Osteoporos Int; 2008 May; 19(5):681-6. PubMed ID: 17968610
    [Abstract] [Full Text] [Related]

  • 13. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 14. Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
    Osaki M, Tatsuki K, Hashikawa T, Norimatsu T, Chiba K, Motokawa S, Furuichi I, Doiguchi Y, Aoyagi K, Shindo H.
    Osteoporos Int; 2012 Feb; 23(2):695-703. PubMed ID: 21394496
    [Abstract] [Full Text] [Related]

  • 15. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
    Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY.
    Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R.
    Osteoporos Int; 2000 Oct; 11(1):83-91. PubMed ID: 10663363
    [Abstract] [Full Text] [Related]

  • 17. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A, Adachi JD, Guyatt G, Papaioannou A, Robinson VA, Shea BJ, Tugwell P, Waldegger LM, Weaver B, Wells G, Zytaruk N.
    Cochrane Database Syst Rev; 2007 Jul 18; (1):CD004523. PubMed ID: 17636764
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
    Health Technol Assess; 2005 Jun 18; 9(22):1-160. PubMed ID: 15929857
    [Abstract] [Full Text] [Related]

  • 20. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD004523. PubMed ID: 18254053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.